https://www.fortunebusinessinsights.com/autoinjectors-market-108507


https://www.fortunebusinessinsights.com/autoinjectors-market-108507

The global autoinjectors market was valued at USD 120.21 billion in 2023 and is projected to
grow from USD 131.45 billion in 2024 to USD 311.33 billion by 2032, registering a CAGR of
11.4% during the forecast period. North America led the autoinjectors market in 2024,
accounting for a dominant market share of 59.2%.
The autoinjectors market is witnessing steady growth globally, driven by the increasing
prevalence of chronic conditions such as diabetes, multiple sclerosis, and rheumatoid arthritis.
The rising demand for self-administration of drugs, along with the convenience, safety, and
accuracy offered by autoinjector devices, is enhancing their adoption across healthcare
settings. Technological advancements, user-friendly designs, and growing awareness among
patients are further contributing to the market expansion. Additionally, the shift toward home-
based healthcare and the rising use of biologics are expected to support the continued growth
of the autoinjectors market in the coming years.
Tariff Impact Analysis for Autoinjectors Market:
https://www.fortunebusinessinsights.com/autoinjectors-market-108507

Autoinjectors Market Overview
The autoinjectors market is experiencing significant growth, driven by the rising prevalence of
chronic diseases such as diabetes, rheumatoid arthritis, and multiple sclerosis. The increasing
demand for self-administration of medications, coupled with advancements in drug delivery
technologies, is propelling the expansion of the autoinjectors market. Additionally, the
convenience and ease of use offered by autoinjectors are encouraging their adoption among
patients and healthcare providers alike.

Market Segmentation
The autoinjectors market is segmented based on type, application, route of administration,
end-user, and region:
• By Type: The market is divided into disposable and reusable autoinjectors. Disposable
autoinjectors are preferred for their single-use convenience and reduced risk of
contamination, while reusable autoinjectors offer cost-effectiveness and environmental
benefits.
• By Application: Key applications include rheumatoid arthritis, diabetes, multiple
sclerosis, anaphylaxis, and other therapies. The management of chronic conditions like
rheumatoid arthritis and diabetes significantly contributes to market demand.
• By Route of Administration: Autoinjectors are primarily used for subcutaneous and
intramuscular injections. Subcutaneous administration is favored for its ease and patient
comfort, especially in home care settings.
• By End-User: The market caters to hospitals & clinics, home care settings, and
ambulatory surgical centers. The home care segment is expanding rapidly due to the
growing trend of self-administration and home-based healthcare.

List of Key Autoinjectors Companies Profiled:
• Viatris Inc. (U.S.)
• Teva Pharmaceuticals, Inc. (Netherlands)
• Ypsomed AG (Switzerland)
• Recipharm AB (Sweden)
• Becton Dickinson and Company (U.S.)
• Halozyme, Inc. (U.S.)
• AstraZeneca (U.K.)
• Bristol-Myers Squibb (U.S.)
• Phillips-Medisize (U.S.)
• SHL Medical AG (Switzerland)
• Xeris Pharmaceuticals, Inc. (U.S.)

Restraining Factors
Despite the positive outlook, the autoinjectors market faces certain challenges:
• High Costs: The expense associated with autoinjectors can be a barrier, particularly in
developing regions where affordability is a concern.
• User Errors: Some patients may experience difficulties in using autoinjectors correctly,
leading to potential treatment failures or adverse effects.
• Alternative Drug Delivery Methods: The emergence of alternative delivery systems,
such as prefilled syringes and wearable injectors, may pose competition to traditional
autoinjectors.

Regional Analysis
• North America: This region holds a significant share of the autoinjectors market,
attributed to advanced healthcare infrastructure, high prevalence of chronic diseases,
and strong presence of key market players.
• Europe: Europe follows closely, with increasing adoption of biologics and biosimilars,
supportive regulatory frameworks, and a growing geriatric population contributing to
market growth.
• Asia Pacific: The region is anticipated to witness the fastest growth, driven by rising
healthcare expenditure, increasing awareness of self-administration, and expanding
access to healthcare services.
• Latin America and Middle East & Africa: These regions are experiencing gradual growth
in the autoinjectors market, supported by improving healthcare infrastructure and
growing awareness of chronic disease management.

Key Industry Developments:
In May 2023, Boehringer Ingelheim International GmbH announced that the U.S. FDA approved
the Cyltezo Pen, an autoinjector for Cyltezo (adalimumab), which is an FDA-approved
interchangeable biosimilar to Humira.